Modernizing clinical trial eligibility: Recommendations of the American society of clinical oncology-friends of cancer research minimum age working group

Journal of Clinical Oncology

Volumn 35, Issue 33, 2017, Pages 3781-3787

  Gore, Lia ^a   Ivy, S Percy ^b   Balis, Frank M ^d   Rubin, Eric ^e   Thornton, Katherine ^f   Donoghue, Martha ^c   Roberts, Samantha ^g   Bruinooge, Suanna ⁱ   Ersek, Jennifer ^j   Goodman, Nancy ^h   Schenkel, Caroline ⁱ   Reaman, Gregory ^c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g Friends of Cancer Research and Genentech   (United States)

^h Kids v Cancer   (United States)

ⁱ ASCO   (United States)

^j LEVINE CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG RESEARCH; HODGKIN DISEASE; HUMAN; MEDICAL SOCIETY; MELANOMA; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SARCOMA; MEDICAL RESEARCH; ONCOLOGY; PROCEDURES; UNITED STATES;

AGE FACTORS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; UNITED STATES;

EID: 85034439657     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.4144     Document Type: Article

References (41)

1. Adamson PC: Improving the outcome for children with cancer: Development of targeted new agents. CA Cancer J Clin 65:212-220, 2015
2. Heron M: Leading causes for 2010. Natl Vital Stat Rep 62:1-96, 2013
3. Smith M, Ries L, Gurney J: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. https://seer.cancer. gov/archive/publications/childhood/childhood-monograph. pdf
4. Hudson MM, Mertens AC, Yasui Y, et al: Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 290:1583-1592, 2003
5. Bottomley SJ, Kassner E: Late effects of childhood cancer therapy. J Pediatr Nurs 18:126-133, 2003
6. Alliance for Childhood Cancer, American Cancer Society: Translating Discovery into Cures for Children with Cancer: Childhood Cancer Research Landscape Report. http://www.cancer.org/acs/groups/content/ @editorial/documents/document/acspc-048347.pdf
7. Kim ES, Bernstein D, Hilsenbeck SG, et al: Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol 33:2815-2820, 2015
8. Beaver JA, Ison G, Pazdur R: Reevaluating eligibility criteria: Balancing patient protection and participation in oncology trials. N Engl J Med 376: 1504-1505, 2017
9. Garaventa A, Luksch R, Lo Piccolo MS, et al: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039, 2003
10. Puduvalli VK, Yung WKA, Hess KR, et al: Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22: 4282-4289, 2004
11. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13: 1011-1019, 2012
12. Balis FM, Thompson PA, Mosse YP, et al: First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: A report on ADVL0912 from the Children's Oncology Group phase 1/pilot consortium. Cancer Chemother Pharmacol 79:181-187, 2017
13. Mossé YP, LimMS, Voss SD, et al: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 14:472-480, 2013
14. Lee DP, Skolnik JM, Adamson PC: Pediatric phase I trials in oncology: An analysis of study conduct efficiency. J Clin Oncol 23:8431-8441, 2005
15. Gore L, DeGregori J, Porter CC: Targeting developmental pathways in children with cancer: What price success?. Lancet Oncol 14:e70-e78, 2013
16. May WA, Gishizky ML, Lessnick SL, et al: Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNAbinding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 90:5752-5756, 1993
17. Dagher R, Pham TA, Sorbara L, et al: Molecular confirmation of Ewing sarcoma. J Pediatr Hematol Oncol 23:221-224, 2001
18. de Alava E, Kawai A, Healey JH, et al: EWSFLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16:1248-1255, 1998
19. Cheng J, Zhu H, Choi JK: CD30 expression in pediatric neoplasms, study of 585 cases. Pediatr Dev Pathol 20:191-196, 2017
20. Pierce JM, Mehta A: Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Rev Hematol 10:29-37, 2017
21. Alperovich A, Younes A: Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma. Cancer J 22:23-26, 2016
22. Xu ML, Acevedo-Gadea C, Seropian S, et al: Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 69: 155-158, 2016
23. Hapgood G, Savage KJ: The biology and management of systemic anaplastic large cell lymphoma. Blood 126:17-25, 2015
24. Martinelli G, Boissel N, Chevallier P, et al: Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study. J Clin Oncol 35:1795-1802, 2017
25. Gökbuget N, Zugmaier G, Klinger M, et al: Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica 102:e132-e135, 2017
26. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 16:57-66, 2015
27. von Stackelberg A, Locatelli F, Zugmaier G, et al: Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381-4389, 2016
28. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
29. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-528, 2015
30. Gardner RA, Finney O, Annesley C, et al: Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322-3331, 2017
31. Gill S, Porter DL: CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: Rules of the road. Expert Opin Biol Ther 14:37-49, 2014
32. Locke FL, Neelapu SS, Bartlett NL, et al: Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 25: 285-295, 2017
33. Institute of Medicine: Safe and Effective Medicines for Children: Pediatric Studies Conducted Under BPCA and PREA. Washington, DC, The National Academies Press, 2012
34. Field MJ, Boat TF: Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington, DC, The National Academies Press, 2012
35. US Food and Drug Administration: Draft guidance for industry: How to comply with the Pediatric Research Equity Act. http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatory information/guidances/ucm079756.pdf
36. Best Pharmaceuticals for Children Act (January 4, 2002) Pub Law 107-109, 107th Congress
37. Chuk MK, Mulugeta Y, Roth-Cline M, et al: Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res 23:9-12, 2017
38. US Food and Drug Administration: FDA approves first therapy for high-risk neuroblastoma. https://www.fda.gov/newsevents/newsroom/press announcements/ucm437460.htm
39. US Food and Drug Administration: FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm560167.htm
40. Federman N, Albert CM, Turpin B, et al: Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer. J Clin Oncol 35, 2017 (suppl; abstr TPS10577)
41. Hyman DM, Laetsch TW, Kummar S, et al: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501)